Single-chain antibody specifically binding MG7, highly glycosylated CEA and use thereof in detection and therapy
US11266688B2 · kind B2 · utility
0Cited by
2References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 27, 2017 |
| Grant date | Mar 8, 2022 |
| Priority date | — |
| Expiry date | Sep 15, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a glycosylated CEA-specific single-chain antibody, and a chimeric antigen receptor (CAR) targeting a glycosylated CEA, which can be used in manufacture of an agent or a medicament for diagnosis or treatment of a tumor overexpressing glycosylated CEA.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.